A new international pricing analysis by America First Healthcare underscores a stark reality: the United States remains the most expensive country in the world for brand-name prescription drugs. The report finds that average prices in the U.S. stand at $508.48, about 759 percent higher than the global median, placing it in a category of its own.
The rising cost of healthcare is steadily reshaping household budgets across the country. In some communities, families now spend more on medical expenses than on housing. Even relatively healthy Americans continue to pay for comprehensive insurance plans, with premiums climbing year after year, largely as a safeguard against unexpected medical emergencies.
This imbalance becomes especially visible at pharmacy counters. Prescription drug prices are among the most unpredictable and frustrating aspects of the healthcare system. For many commonly used medications, Americans pay several times more than patients in other countries for the same treatments.
The analysis highlights wide price variations, not only globally but also within the U.S. retail market, pointing to deeper structural inefficiencies. Expanding price transparency and reforming how prescription drugs are priced could improve accountability and give consumers greater control.
The gap is evident in country comparisons. In Canada, the average cost of similar medications is $263.53, roughly half the U.S. price. In the United Arab Emirates, the average drops further to $140.33, meaning Americans pay more than three and a half times as much.
The U.S. tops the list for several widely used drugs, including Viagra, Lyrica, Lipitor, Prozac, Xanax, Zestril, Viread, and Humira, with prices often exceeding global benchmarks by anywhere between 800 percent and 4,000 percent.
One of the most striking examples is Humira, used to treat conditions such as rheumatoid arthritis. A month’s supply in the U.S. costs around $7,300. In Australia, the same treatment is priced at just $8.70, a difference of more than 800 times.
Similar patterns emerge with everyday medications. Prozac is priced at $14.50 in the U.S. but costs only $0.08 in Vietnam. Viagra, which costs $85.70 in the U.S., is available for $0.80 in Egypt. These are not marginal differences but dramatic markups on widely used drugs.
Newer treatments show slightly different trends. Semaglutide, sold under brands like Ozempic, Wegovy, and Rybelsus, ranges from $148.11 in the Philippines to $0.71 in Vietnam. While the U.S. is not the most expensive market in this case, the global inconsistency remains significant.
Much of the cost disparity is tied to the nature of branded, patented drugs. Pharmaceutical companies invest heavily in research, clinical trials, regulatory approvals, and marketing. These expenses are often built into retail pricing, contributing to higher costs for consumers.
READ: 5 Indian Americans among 2026 TIME100 Health (
As healthcare expenses rise, price transparency has become a central policy issue. The Affordable Care Act laid the foundation for greater transparency by requiring hospitals to publish standard charges and negotiated insurance rates. Building on that, the proposed Healthcare PRICE Transparency Act 2.0 aims to strengthen enforcement and make pricing data more accessible and easier to understand.
These reforms are designed to help patients compare costs for common services and give employers and insurers more leverage in negotiating rates. Prescription drug pricing is also under increasing scrutiny, with policymakers exploring ways to curb rising costs.
Recent federal measures include caps on insulin copayments in certain regions and expanded authority for Medicare to negotiate prices for select high-cost drugs. At the same time, pharmacy benefit managers, or PBMs, are facing growing attention for their role in determining how drug prices are set behind the scenes.
For many Americans, rising insurance premiums and limited coverage options are prompting a reassessment of healthcare spending. Consumers are increasingly seeking plans that offer better value and more control over costs.
The analysis ultimately points to more than just high prices. It reveals wide inconsistencies across countries, brands, and even within the U.S. itself. Greater transparency and structural reforms, experts say, could help rebalance the system and make healthcare pricing more predictable and fair.
The study evaluated publicly listed medicine prices across 34 countries using a standardized comparison model. Prices were drawn from government databases, national formularies, pharmacy listings, and hospital fee schedules. Each drug was matched by active ingredient, dosage, and comparable package size, then converted into U.S. dollars per unit using prevailing exchange rates to ensure consistency across markets.
This report is based on the study shared by America First Healthcare